Trevi Therapeutics (NASDAQ:TRVI – Get Rating) will be releasing its earnings data after the market closes on Thursday, August 11th. Analysts expect Trevi Therapeutics to post earnings of ($0.21) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.
Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.07. During the same period in the previous year, the company earned ($0.43) EPS. On average, analysts expect Trevi Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.Get Trevi Therapeutics alerts:
Trevi Therapeutics Stock Performance
Shares of TRVI opened at $4.09 on Wednesday. The business's fifty day simple moving average is $2.99 and its two-hundred day simple moving average is $2.21. The company has a market cap of $158.23 million, a price-to-earnings ratio of -3.03 and a beta of 0.21. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.67. Trevi Therapeutics has a 12 month low of $0.46 and a 12 month high of $4.68.
Insider ActivityIn other news, major shareholder Tpg Gp A, Llc sold 436,431 shares of the firm's stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $2.86, for a total transaction of $1,248,192.66. Following the completion of the transaction, the insider now owns 3,888,452 shares in the company, valued at $11,120,972.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 546,128 shares of company stock worth $1,572,283 over the last 90 days. Corporate insiders own 39.52% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in Trevi Therapeutics in the first quarter worth about $44,000. State Street Corp purchased a new position in shares of Trevi Therapeutics during the first quarter valued at approximately $81,000. Finally, Vanguard Group Inc. raised its stake in shares of Trevi Therapeutics by 7.6% during the first quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock valued at $336,000 after acquiring an additional 10,780 shares in the last quarter. Hedge funds and other institutional investors own 75.34% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently commented on TRVI shares. Needham & Company LLC raised their target price on Trevi Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, June 29th. Oppenheimer raised their target price on Trevi Therapeutics to $12.00 in a report on Monday, July 4th.
About Trevi Therapeutics
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- CVS and Walgreens Show Why Investment Objectives Matter
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.